Coffee Shoppe

[ProfitScout]

$CYCA Reticulate Micro Launches $10M Reg A Capital Raise
Link: https://reticulate.io/reticulate-micro-launches-10m-reg-a-capital-raise/

Digital Offering Allows Defense Tech Provider to Democratize its Offering to Public Investors

PALM BAY, Fla. / August 1, 2024 / Reticulate Micro, Inc. (“Reticulate Micro,” “Reticulate” or the “Company”), a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, has launched its Regulation A stock offering to raise up to $10 million (the “Reg A Offering”) to support Reticulate’s product and market launch efforts as a leading provider of video compression and tactical and SATCOM management solutions. Its flagship product, VAST™, is designed to enable ultra-efficient streaming video and situational awareness in bandwidth-challenged environments.

Reticulate’s offering was qualified with the Securities and Exchange Commission (“SEC”) this week and allows anyone to now invest in the Company. The Reg A Offering has an offering price of $3.50 per unit. Each unit includes one share of the Company’s Class A Common Stock and one warrant to purchase one share of the Company’s Class A Common Stock at an exercise price of $5.50 per share. The minimum investment is $700 for 200 units and is open to all investors.

The lead selling agents for the transaction include Boustead Securities, LLC, a leading full-service investment banking firm and licensed FINRA member, and Digital Offering LLC, a next-generation investment bank focused on technology and innovation and helping high-quality private and public growth companies access U.S. capital markets.

“We are delighted to launch our capital raise with such an experienced investment banking team who share our vision to democratize our offering to a broad investment pool,” said Michael Chermak, Executive Chairman of Reticulate Micro.

Reticulate will utilize the DealMaker platform which allows the public to invest directly in Reticulate’s stock: https://invest.reticulate.io

The Company plans to use the proceeds from the Reg A Offering to scale sales and marketing as well as operations, invest in new product development, and expand its IP portfolio.

“We are excited to leverage the funds from our Reg A Offering to accelerate the development and delivery of our cutting-edge VAST™ video compression technology, ensuring we stay at the forefront of innovation in national security, healthcare, and critical infrastructure,” said Joshua Cryer, President and CEO of Reticulate Micro.

Investors can receive additional information on the offering either on Reticulate’s investor page at https://reticulate.io/investors/ or via email at [e-mail].

About Reticulate Micro, Inc.

Reticulate Micro, Inc., with headquarters in Palm Bay, Florida, is a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment. Reticulate is building one of the world’s first post-quantum-encrypted open-systems platforms for robust video streaming, simplified terminal management and satellite mobile connectivity in austere environments and diverse orbital regimes.?Serving the defense, mobility, broadcasting, enterprise infrastructure monitoring and security sectors, Reticulate Micro and its newest business segment Reticulate Space embrace open standards across its software and product offerings.

Cautionary Note Regarding Forward-Looking Statements:

This press release contains forward-looking statements that are subject to various risks and uncertainties. In addition, our representatives or we may make forward-looking statements orally or in writing from time to time. We base these forward-looking statements on our expectations and projections about future events, which we derive from the available information. Such forward-looking statements relate to future events or our future performance, including our financial performance and projections, revenue and earnings growth, and business prospects and opportunities. You can identify forward-looking statements by those that are not historical facts, particularly those that use terminology such as “intends,” “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms.

Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Company does not undertake any duty to update any forward-looking statements except as may be required by law.

The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by the Company are highly speculative. Investing in shares of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.

The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on the Company, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.

Contact:

Media:
Reticulate Micro Media Relations
[e-mail]

Investor Relations:
Reticulate Micro Investor Relations

[ProfitScout]

$IVDN (16 million float) is about to file a banner quarterly report for its fiscal Q2 which will show that sales of its superior Insultex House Wrap product have already exceeded all of the company's results for the full 2023 fiscal year.

This has been pre-announced in the last two IVDN news releases:

Innovative Designs Sales Update
May 30, 2024
https://finance.yahoo.com/news/innovative-designs-sales-110000236.html

Innovative Designs Vendor Growth
April 10, 2024
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html

[ProfitScout]

$IDVV: Corporate Update

CARLSBAD, CA, August 1, 2024 (OTCMARKETS) -- International Endeavors Corp. ("IEC") (OTC PINK: IDVV), a technology holdings company announced the following statement.

The company WITech division has finalized its agreement to launch Winners Waygers an AI (Artificial intelligence) based sports handicapping service developed an to assist with picking winners, research, and odds management for fantasy leagues, and professional sports handicapping (NFL, NBA, UFC, MLB, MLS) and Horse betting.

Currently the service is being used by professional handicappers and WITech plans to bring the service mainstream beginning with the NFL Season, then expanding it out to other mainstream sports. A slow launch is necessary due to the complexity that only professional handicappers can understand. We want to make the service very simple and easy to use as we roll it out mainstream.

We are planning to launch in phases. Starting with a limited time only free beta site by August 15th that will allow users to sign up for NFL picks, combined with data and research. Following phases we anticipate rolling out in Q4 will begin to combine additional sports and a generative AI bot that will allow paying members to ask handicapping questions and receive data to assist the in making bets.

To address the questions about the July release. Our initial plans were to begin the launch in July, but we had to secure portions of the backend of the website as portions of the backend were corrupted by persons trying to scrape data from the site. We discovered the breach, and have since repaired the issue.

We are launching and we see a massive opportunity for a subscription-based model.

We encourage everyone to follow us.

Twitter

https://twitter.com/IDVVcorp

Website(s)

https://witech.ai

https://IDVVCORP.COM



About Us

International Endeavors Corporation ("IEC") is a technology holdings company.

The Company currently is reporting its financial information on OTCMarkets.

Our filings can be seen at https://www.otcmarkets.com

Disclaimer

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

International Endeavors Corporation

Phone:[phone]

Email:[e-mail]

SOURCE:

International Endeavors Corporation, Inc.

[ProfitScout]

$AVRW Avenir Wellness Solutions™ ($AVRW) Skin Care Products are Sold at Walmart $WMT , Target $TGT , CVS Health $CVS , and Amazon $AMZN Retail Outlets. Accelerating Sales for Superior Anti-Aging Skin Care Line with Direct Endorsement of Nicole Kidman
Click here:
https://www.einpresswire.com/article/660866879/accelerating-sales-for-superior-anti-aging-skin-care-line-with-direct-endorsement-of-nicole-kidman-stock-symbol-avrw

[ProfitScout]

$AVRW News:: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: [phone]
E: [e-mail]

[ProfitScout]

$RENB News: Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward in the fight against cancer.

Traditional cancer detection methods often fall short in identifying cancers at an early stage when treatment is the most effective. However, Flamingo has the potential to overcome these limitations by harnessing the power of AI to analyze minute amounts of cfDNA data that is highly accurate.

"At RenovaroCube, we believe in pushing the boundaries of possibility," states Daan Vessies, senior scientist at RenovaroCube. "Flamingo undescores our commitment to change cancer diagnostics in a transformative way, ultimately offering clinicians a powerful tool to detect cancer across diverse omic layers."

The Company believes that no single model or molecular modality will reach the requisite sensitivity and specificity throughout the entire patient journey for personalized, precision medicine, from early detection, to predicting the effectiveness of various treatment options, to monitoring the response to therapy within days of starting it, to detecting recurrence at the earliest possible moment. Therefore, our AI/machine learning platform, The Cube, integrates multi-omic data, offering a uniquely comprehensive approach to cancer detection by leveraging a library of trained models for multiple omic layers. One such model Flamingo focuses on is the detection of cancer from ultra-low pass whole genome sequencing (ULP-WGS) cfDNA data using fragmentomics.

Flamingo's development marks a significant milestone in the quest for early cancer detection with RenovaroCube’s engine. By utilizing as few as only 200,000 cell-free DNA fragments per sample, integrating fragment lengths, sequence motifs and employing a meticulously designed neural network, Flamingo achieves remarkable performance in distinguishing cancer from healthy samples.

By augmenting The Cube's arsenal of models operating across various omic layers, Flamingo contributes to the development of non-invasive diagnostics to detect cancer early, enabling timely interventions and improving patient outcomes.

"Adding Flamingo to our Cube will accelerate our efforts to realize a paradigm shift in cancer detection," affirms Frank van Asch, CTO, RenovaroCube. "With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process."

RenovaroCube invites interested doctors and scientists from international research institutions, clinical cancer centers and all stakeholders to join in the early research use application of our AI/machine learning platform to advance cancer diagnostics and pave the way for a healthier future.

About Renovaro:

Please see a recent interview with Avram Miller, Member of, and Advisor to, the Board of Directors, former co-founder of Intel Capital and SVP of Business Development for Intel:

https://techbullion.com/avram-miller-talks-about-renovaro-and-its-impact-in-diagnosing-cancers-and-infectious-diseases-with-ai

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes RenovaroBio, with its advanced cell-gene immunotherapy company, and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

https://www.renovarogroup.com

https://www.renovarobio.com

https://www.renovarocube.com

About Cyclomics:
Cyclomics is a Dutch company founded in 2018, winner of the Health Holland Venture Challenge (startup of the year) by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.

https://www.cyclomics.com/

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: [e-mail]

Source: Renovaro Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTEwODQ5OCM2MjI2Njk4IzIxMjA2Nzk=
https://ml.globenewswire.com/media/OThkZGJkYzMtMDEzYi00YTcxLThhZWEtZDdmMDQ2ZDA4NzdlLTExMzIyNTA=/tiny/Renovaro-Inc.png

Source: Renovaro Inc

[ProfitScout]

$RENB News: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.

Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given,” according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.

RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength’ providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection,” added Dr. Henk Viëtor (MD/PHD).

Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq’ for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay in partnership with Oxford Nanopore that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.

"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."

About Renovaro:

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: [e-mail]

Source: Renovaro Inc.

[ProfitScout]

$RENB: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care

LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.

Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.

Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.

Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.

As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.

“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”

Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”

With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.

About Renovaro:

Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.

About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: [e-mail]

Source: Renovaro Inc.

https://www.globenewswire.com/newsroom/ti?nf=OTA5MTc2OSM2MjA3NjI3IzIxMjA2Nzk=
https://ml.globenewswire.com/media/YjM1MjkzZDUtZGE5Yi00MjI0LWI5M2MtMjcxMGI0YThiNzk1LTExMzIyNTA=/tiny/Renovaro-Biosciences-Inc-.png

Source: Renovaro Biosciences Inc.

[ProfitScout]

$RENB: Top 10 Reasons to Have on your RADAR 
https://twitter.com/JediJazz22/status/1777421007134867796/photo/1

[ProfitScout]

$RENB - Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace | NASDAQ https://www.nasdaq.com/press-release/cutting-edge-ai-company-gedicube-and-cyclomics-sign-binding-loi-to-join-forces-and-0

From the article:

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.
Cyclomics’ 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI application
GEDiCube’s award-winning AI is developing high-performance biomarker panels for 13 different cancers.
GEDiCube’s partnership with NVIDIA’s Inception program will help expand to multi-modal capabilities by adding imaging.

[ProfitScout]

$GVH -Experience Effortless E-commerce Shipping: Globavend Holdings Limited (NASDAQ:GVH) Tailored Solutions from Hong Kong to Your Doorstep in Australia & New Zealand!
Click here: https://axecapitalusa.com/gvh/

Welcome to the future of logistics with Globavend Holdings Limited (NASDAQ:GVH), where innovation meets opportunity in the bustling e-commerce landscape of Asia-Pacific. As pioneers in direct injection from Hong Kong & Southern China to Australia and New Zealand, we offer investors a gateway to a market projected to witness exponential growth. Our integrated cross-border logistics solutions ensure seamless parcel consolidation, air freight forwarding, and customs clearance, catering to the evolving needs of online businesses.

Strategic Expansion: With plans to establish ground transportation and customs clearance teams, we are poised to capture a significant market share.

Profitable Partnerships: As an IATA-accredited cargo agent with strong ties to top air freight carriers, we guarantee cost-effective solutions.

Robust Growth: Amidst a booming e-commerce market, our stable business model promises lucrative returns for investors seeking long-term opportunities.

Innovative Solutions: Our all-in-one shipping solution ensures operational efficiency and customer satisfaction, positioning us as industry leaders.

Invest in Globavend today and be part of a transformative journey reshaping the future of global logistics.

[ProfitScout]

$GDHG: Only 27% Of Chinese Citizens Have Visited Amusement Parks, And Demand Is Now Growing – Golden Heaven (NASDAQ: GDHG) Plans To Ride The Wave
Benzinga
April 10, 2024 8:27 AM 
Click here:  
https://www.benzinga.com/partner/emerging-markets/24/04/38181116/only-27-of-chinese-citizens-have-visited-amusement-parks-and-demand-is-now-growing-golde

[ProfitScout]

$GDHG News: Golden Heaven Group Holdings Ltd. Enters into a Collaboration Agreement with Nanping City Dacheng Culture Communication Co., Ltd.

NANPING, China, April 2, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, today announced that on March 29, 2024, it entered into a collaboration agreement (the "Agreement") with Nanping City Dacheng Culture Communication Co., Ltd. ("Dacheng Culture").

Under the Agreement, Golden Heaven has agreed to lease certain land and property to Dacheng Culture to host a range of activities, including wedding photography, family photography, marriage proposal planning, Hanfu (traditional Chinese clothing) photography, and various celebratory events. Dacheng Culture has agreed to compensate the Company with an aggregate lease payment of RMB6 million, payable quarterly, over the contract period, which extends from March 29, 2024 to March 28, 2025.

Mr. Jin Xu, the CEO and Chairman of the Company, commented, "As previously disclosed on March 19, 2024, we entered into a similar collaboration agreement with Zigong City Dragon Culture & Arts Co. Ltd. These collaboration agreements are designed to leverage our park locations and family-oriented attractions, enhance site utilization and strengthen bonds with our guests. The diverse activities that Dacheng Culture plans to introduce to our parks are expected to attract more guests, elevate the guest experience and add to our revenue. We are enthusiastic about embarking on this venture and future collaborations."

About Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.

Forward-Looking Statements

This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Golden Heaven Group Holdings Ltd.
Email: [e-mail]

Ascent Investor Relations LLC
Phone: [phone]
Email: [e-mail]

https://c212.net/c/img/favicon.png?sn=CN77335&sd=2024-04-02 View original content:https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-enters-into-a-collaboration-agreement-with-nanping-city-dacheng-culture-communication-co-ltd-302105015.html

SOURCE Golden Heaven Group Holdings Ltd.

[ProfitScout]

$GDHG - Our parks provide a wide range of exciting and entertaining experiences, thrilling rides, family-friendly attractions, water attractions. FY2023 Revenue 31.8M, FY2023 Gross Profit 19.3M, FY2023 Net Income $6.5M https://ir.jsyoule.com #amusementparks $DIS $SIX $SEAS $GDHG

GDHG - Our parks provide a wide range of exciting and entertaining experiences, thrilling rides, family-friendly attractions, water attractions.
FY2023 Revenue 31.8M, FY2023 Gross Profit 19.3M, FY2023 Net Income $6.5M https://t.co/o6KKIHgysk #amusementparks $DIS $SIX $SEAS $GDHG pic.twitter.com/lEv7u2q9nS

— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) April 1, 2024

[ProfitScout]

$GDHG News: Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000542.html

[ProfitScout]

$GDHG News: Golden Heaven Group Holdings Ltd. to Expand into Indonesia Market with its Strategic Partnership
February 29, 2024
News Link:
https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-to-expand-into-indonesia-market-with-its-strategic-partnership-302074850.html

[ProfitScout]

$HCTI News: Healthcare Triangle Empowers Healthcare Providers to Harness AI and LLMs for Groundbreaking Outcomes

Company’s latest initiative addresses growing demand for AI analytics to revolutionize patient care

PLEASANTON, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” HCTI” or the “Company”), a leader in transforming healthcare through technology, today unveiled an initiative aimed at enabling healthcare organizations to harness the full potential of their organic data through Artificial Intelligence (AI) and Large Language Models (LLMs).

This initiative is set against the backdrop of a rapidly expanding AI market, with Grand View Research estimating the AI in healthcare market size was $22.45 billion in 2020, and is expected to expand at a compounded annual growth rate (CAGR) of 36.4% from 2024 to 2030. Healthcare Triangle's latest offering is poised to empower healthcare providers with the tools to develop and deploy sophisticated machine learning (ML) models and LLMs, significantly enhancing patient outcomes through personalized and predictive healthcare solutions.

A Strategic Response to a Growing Demand:

The surge in the AI and analytics market highlights an escalating need for sophisticated data-driven solutions in healthcare. Healthcare Triangle's initiative strategically addresses this demand by providing a secure, scalable, and compliant digital platform. This platform facilitates the creation of AI and LLMs customized to meet the specific requirements of the healthcare industry. Through the utilization of organic data, healthcare providers gain access to valuable insights and patterns. These insights enable more precise diagnoses, efficient treatments, and ultimately, elevate the standard of patient care.

Key Features of the Initiative:

Secure and Compliant Data Utilization: Prioritizing data security and privacy, Healthcare Triangle ensures all AI and LLM development is in strict compliance with healthcare regulations, including HITRUST certification and HIPAA compliance. This commitment extends to a secure environment for data transfer, storage, and processing, alongside a comprehensive disaster recovery strategy.
Scalable Infrastructure Ready for the Future: Designed to meet the growing demands of healthcare organizations, the initiative's infrastructure is built for scalability, accommodating increasing data volumes and computational needs without compromising performance. A secure, cloud-hosted lab for LLM development highlights the initiative's readiness for the future, ensuring safety and efficiency in AI and analytics deployment.
Collaborative Ecosystem for Shared Innovation: Facilitating a culture of collaboration, the platform encourages the sharing of insights and methodologies within and between organizations, fostering a community focused on improving patient care and aligning with industry standards.
Customizable AI and LLM Development: Recognizing the diverse needs within healthcare, Healthcare Triangle offers customizable tools and solutions for developing AI and LLM models directly aligned with healthcare outcomes and objectives, ensuring flexibility and cost-effectiveness in platform service management.
A Vision for the Future of Healthcare:

"With the AI and analytics market projected to quadruple by 2024, our initiative represents a timely and necessary leap forward in empowering healthcare providers," stated Anand Kumar, Chief Revenue Officer of Healthcare Triangle. "We are not just advancing technology; we are setting a new standard for patient care, leveraging AI and LLMs to deliver personalized, predictive, and effective healthcare solutions."

As the AI and analytics market continues to grow, Healthcare Triangle's initiative marks a critical step towards realizing a future where healthcare is more personalized, outcomes are improved, and patients receive the care they need, when they need it, setting a new benchmark in healthcare innovation.

About Healthcare Triangle:

Healthcare Triangle, Inc., headquartered in Pleasanton, California, stands at the forefront of healthcare technology, specializing in AI and digital transformation. With a commitment to innovation, collaboration, and excellence, Healthcare Triangle is dedicated to reshaping healthcare delivery for the better. We collaborate with healthcare entities, including hospitals, health systems, payers, and pharma/life sciences organizations, leveraging breakthrough technology and extensive industry expertise to enhance health outcomes through optimized data utilization and cutting-edge information technologies. Holding HITRUST Certification for Cloud and Data Platform (CaDP) – featuring CloudEz™, DataEz™, and readabl.AI – our commitment to the highest standards in data protection and information security is unwavering. Healthcare Triangle serves as a beacon for the adoption of new technologies, data enlightenment, business agility, and swift response to evolving business needs and competitive challenges. Thriving in the highly regulated healthcare and life sciences sectors, we excel in digital transformation encompassing the cloud, security and compliance, identity management, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. For more information, visit www.healthcaretriangle.com

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on March 28, 2023, subsequent filings and future reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Contacts
Investors:
1-800-617-9550
[e-mail]

https://www.globenewswire.com/newsroom/ti?nf=OTA0MjA2NSM2MDg0Mjc4IzUwMDEyMTA5OA==
https://ml.globenewswire.com/media/YjI0OWY5YWQtNmMwZC00ZGQwLTg3ODUtNzZhNjcyYjg1NzQxLTUwMDEyMTA5OA==/tiny/Healthcare-Triangle-Inc.png

Source: Healthcare Triangle, Inc